Copyright
©The Author(s) 2018.
World J Clin Cases. May 16, 2018; 6(5): 74-83
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Table 6 Adverse events of sorafenib plus transarterial chemoembolization treatment and transarterial chemoembolization treatment alone
| Fatigue | Diarrhea | Rash | Nausea | HFS | Hypertensive | Vomiting | Bone marrow suppression | |
| Sorafenib + TACE (38) | 17 | 13 | 12 | 10 | 15 | 12 | 9 | 11 |
| TACE (29) | 10 | 4 | 2 | 3 | 0 | 3 | 3 | 5 |
| χ2 | 0.066 | 3.062 | 6.062 | 4.019 | 14.749 | 4.268 | 3.378 | 1.24 |
| P value | 0.793 | 0.061 | 0.014 | 0.056 | 0.000 | 0.039 | 0.066 | 0.265 |
- Citation: Lei XF, Ke Y, Bao TH, Tang HR, Wu XS, Shi ZT, Lin J, Zhang ZX, Gu H, Wang L. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World J Clin Cases 2018; 6(5): 74-83
- URL: https://www.wjgnet.com/2307-8960/full/v6/i5/74.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v6.i5.74